Program
QY201
A development code. Also written as “QY201 Tablets(10mg)”, “QY201 Tablets(20mg)” and “QY201 Tablets(5mg)”.
Its studies are mostly in Dermatitis, Atopic · Vitiligo, led by E-nitiate Biopharmaceuticals (Hangzhou).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| E-nitiate Biopharmaceuticals (Hangzhou) | 43 open or running | phase 3since Sep 10, 2025 | Aug 28, 2022 | Dec 31, 2026phase 2 · NCT07712523 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 28, 2022First study: phase 2 study in Dermatitis, AtopicFirst studyNCT05525715 · 260 planned
- Sep 10, 2025Phase 3 study in Dermatitis, AtopicNCT07180511 · 460 planned · China
- Jul 14, 20262 phase 2 studiesNCT07712536, NCT07712523
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Adult Subjects With Non-Segmental VitiligoNCT07712523
- May 18, 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07180511
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07712536Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD) · China | 2 | Completed | Dec 19, 2025 | 24 |
| NCT07712523Adult Subjects With Non-Segmental Vitiligo · China | 2 | Recruiting | Dec 31, 2026 | 200 |
| NCT07180511Dermatitis, Atopic · China | 3 | By invitation | May 18, 2027 | 460 |
| NCT05525715Dermatitis, Atopic | 2 | Not yet recruiting | Dec 2025 | 260 |
How it is read
Names in the registry
- “QY201 Tablets(10mg)”, 2 entries
- “QY201 Tablets(20mg)”, 2 entries
- “QY201 Tablets(5mg)”, 1 entry
- “10mg QY201 tablet”, 1 entry
- “20mg QY201 tablet”, 1 entry
Codes read as this program: QY201.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 3 studies
- Vitiligo, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.